ADMA
Price
$19.72
Change
+$0.47 (+2.44%)
Updated
Dec 3 closing price
Capitalization
4.69B
105 days until earnings call
Intraday BUY SELL Signals
CPRX
Price
$23.09
Change
+$0.47 (+2.08%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
2.79B
105 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ADMA vs CPRX

Header iconADMA vs CPRX Comparison
Open Charts ADMA vs CPRXBanner chart's image
ADMA Biologics
Price$19.72
Change+$0.47 (+2.44%)
Volume$2.64M
Capitalization4.69B
Catalyst Pharmaceuticals
Price$23.09
Change+$0.47 (+2.08%)
Volume$22.45K
Capitalization2.79B
ADMA vs CPRX Comparison Chart in %
View a ticker or compare two or three
VS
ADMA vs. CPRX commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADMA is a StrongBuy and CPRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (ADMA: $19.26 vs. CPRX: $22.61)
Brand notoriety: ADMA and CPRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADMA: 36% vs. CPRX: 30%
Market capitalization -- ADMA: $4.61B vs. CPRX: $2.79B
ADMA [@Biotechnology] is valued at $4.61B. CPRX’s [@Biotechnology] market capitalization is $2.79B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADMA’s FA Score shows that 2 FA rating(s) are green whileCPRX’s FA Score has 2 green FA rating(s).

  • ADMA’s FA Score: 2 green, 3 red.
  • CPRX’s FA Score: 2 green, 3 red.
According to our system of comparison, CPRX is a better buy in the long-term than ADMA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADMA’s TA Score shows that 5 TA indicator(s) are bullish while CPRX’s TA Score has 4 bullish TA indicator(s).

  • ADMA’s TA Score: 5 bullish, 4 bearish.
  • CPRX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ADMA is a better buy in the short-term than CPRX.

Price Growth

ADMA (@Biotechnology) experienced а +0.26% price change this week, while CPRX (@Biotechnology) price change was -4.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

ADMA is expected to report earnings on Mar 19, 2026.

CPRX is expected to report earnings on Mar 18, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ADMA($4.69B) has a higher market cap than CPRX($2.79B). ADMA has higher P/E ratio than CPRX: ADMA (22.91) vs CPRX (13.27). ADMA YTD gains are higher at: 12.303 vs. CPRX (8.337). CPRX has higher annual earnings (EBITDA): 281M vs. ADMA (163M). CPRX has more cash in the bank: 653M vs. ADMA (90.3M). CPRX has less debt than ADMA: CPRX (2.99M) vs ADMA (83.8M). CPRX has higher revenues than ADMA: CPRX (558M) vs ADMA (474M).
ADMACPRXADMA / CPRX
Capitalization4.69B2.79B168%
EBITDA163M281M58%
Gain YTD12.3038.337148%
P/E Ratio22.9113.27173%
Revenue474M558M85%
Total Cash90.3M653M14%
Total Debt83.8M2.99M2,802%
FUNDAMENTALS RATINGS
ADMA vs CPRX: Fundamental Ratings
ADMA
CPRX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
2920
SMR RATING
1..100
1633
PRICE GROWTH RATING
1..100
4648
P/E GROWTH RATING
1..100
9876
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CPRX's Valuation (63) in the Pharmaceuticals Other industry is in the same range as ADMA (74) in the Biotechnology industry. This means that CPRX’s stock grew similarly to ADMA’s over the last 12 months.

CPRX's Profit vs Risk Rating (20) in the Pharmaceuticals Other industry is in the same range as ADMA (29) in the Biotechnology industry. This means that CPRX’s stock grew similarly to ADMA’s over the last 12 months.

ADMA's SMR Rating (16) in the Biotechnology industry is in the same range as CPRX (33) in the Pharmaceuticals Other industry. This means that ADMA’s stock grew similarly to CPRX’s over the last 12 months.

ADMA's Price Growth Rating (46) in the Biotechnology industry is in the same range as CPRX (48) in the Pharmaceuticals Other industry. This means that ADMA’s stock grew similarly to CPRX’s over the last 12 months.

CPRX's P/E Growth Rating (76) in the Pharmaceuticals Other industry is in the same range as ADMA (98) in the Biotechnology industry. This means that CPRX’s stock grew similarly to ADMA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADMACPRX
RSI
ODDS (%)
Bearish Trend 6 days ago
77%
Bearish Trend 6 days ago
87%
Stochastic
ODDS (%)
Bearish Trend 6 days ago
79%
Bearish Trend 6 days ago
77%
Momentum
ODDS (%)
Bullish Trend 6 days ago
76%
Bullish Trend 6 days ago
86%
MACD
ODDS (%)
Bullish Trend 6 days ago
90%
Bullish Trend 6 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 6 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 6 days ago
81%
Advances
ODDS (%)
Bullish Trend 9 days ago
86%
Bullish Trend 9 days ago
80%
Declines
ODDS (%)
Bearish Trend 17 days ago
74%
Bearish Trend 6 days ago
67%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
75%
Bearish Trend 6 days ago
72%
Aroon
ODDS (%)
N/A
Bullish Trend 6 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ADMA
Daily Signal:
Gain/Loss:
CPRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSUAX25.45N/A
N/A
Cohen & Steers Global Infrastructure A
ASIRX12.43N/A
N/A
Alger Small Cap Growth Institutional R
TSCSX32.95N/A
N/A
Thrivent Small Cap Stock S
JANEX149.71N/A
N/A
Janus Henderson Enterprise D
IRCIX13.17N/A
N/A
Voya Russell Small Cap Index Port S2

ADMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with OCUL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADMA
1D Price
Change %
ADMA100%
-0.62%
OCUL - ADMA
43%
Loosely correlated
-3.93%
VIR - ADMA
40%
Loosely correlated
-7.17%
XENE - ADMA
40%
Loosely correlated
-1.45%
CPRX - ADMA
40%
Loosely correlated
-0.35%
IMTX - ADMA
39%
Loosely correlated
-3.70%
More

CPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CPRX has been loosely correlated with VIR. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CPRX jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPRX
1D Price
Change %
CPRX100%
-0.35%
VIR - CPRX
50%
Loosely correlated
-7.17%
SANA - CPRX
48%
Loosely correlated
-0.88%
IRON - CPRX
43%
Loosely correlated
-2.16%
ADMA - CPRX
41%
Loosely correlated
-0.62%
SYRE - CPRX
41%
Loosely correlated
-0.91%
More